Q-omics provides the consensus-scored DEFA6 profile across patient tissues and cancer cell-line models. DEFA6 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DEFA6 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, DEFA6 RNA expression shows 8,865 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, COAD, and THYM as cancer lineages where DEFA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFA6 survival associations across molecular data types. DEFA6 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFA6 RNA expression–survival associations across cancer types. High DEFA6 expression shows unfavorable associations in LUSC, CESC, SCLC, PCPG and DLBC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for DEFA6 RNA expression.
This table summarizes DEFA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DEFA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFA6 shows lower tumor expression in STAD and LUAD and higher tumor expression in COAD, READ, HNSC and LIHC. The COAD box plot shows higher DEFA6 RNA expression in tumor versus normal tissue (log2 FC = +2.183, t-test p < 0.001).
This table shows molecular features associated with DEFA6 in patient tissues and cancer cell lines. In patient samples, DEFA6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
